Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease

Next Previous
Trial Profile

A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2017

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use; Pharmacokinetics

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 May 2017 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top